Recorded 402.5 Billion Yen Additional Provision For Legal Proceedings After U.S. Jury Verdict In Antitrust Litigation
BRIEF-Takeda Pharmaceutical Co: Recorded 402.5 Billion Yen Additional Provision For Legal Proceedings After U.S. Jury Verdict In Antitrust Litigation June 5 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T:
TAKEDA PHARMACEUTICAL CO LTD - ADDITIONAL PROVISION FOR LEGAL PROCEEDINGS AND REVISION OF EARNINGS REPORT (KESSAN TANSHIN) FOR FISCAL YEAR ENDED MARCH 31, 2026 (IFRS,CONSOL)
TAKEDA PHARMACEUTICAL CO - RECORDED AN ADDITIONAL PROVISION FOR LEGAL PROCEEDINGS OF JPY 402.5 BILLION AND RECOGNIZED RELATED TAX BENEFITS OF JPY 58.4 BILLION IN THE CONSOLIDATED FINANCIAL STATEMENTS FOR FY2025
TAKEDA PHARMACEUTICAL CO - THIS REVISION HAS NO IMPACT ON TAKEDA’S CORE FINANCIAL RESULTS FOR FY2025, NO CHANGES TO THE FY2026 FINANCIAL FORECAST OR MANAGEMENT GUIDANCE, INCLUDING THE FORECAST FOR ADJUSTED FREE CASH FLOW
Source text: ID:nTSre89a71
Further company coverage: 4502.T
(Reporting by Kantaro Komiya)
((Kantaro.Komiya@thomsonreuters.com;))
Recent news on Takeda Pharmaceutical
See all newsTakeda launches sleep disorder pill in the US after DEA clearance removes final hurdle (updated)
Brief: Takeda's Orzeyful Available In U.S. By Prescription To Treat Narcolepsy Type 1 In Adults
Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle
Takeda Pharmaceutical Company Limited reports results for the quarter ended September 30 - Earnings Summary
Table: Takeda Pharmaceutical Company Limited -6-MTH group results (IFRS)